Follow

Both SGLT-2 inhibitors and GLP-1 receptor agonists reduce cardiovascular risk () in type 2 mellitus, but they differ with respect to renal function. This may provide a more personalised approach to treatment.

pubmed.ncbi.nlm.nih.gov/373810 doi.org/10.1186/s12933-023-018

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.